Cargando…
Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110
BACKGROUND: Bispecific T cell engager (BiTE(®)) are single-chain bispecific antibody constructs with dual specificity for CD3 on T cells and a surface antigen on target cells. They can elicit a polyclonal cytotoxic T cell response that is not restricted by T cell receptor (TCR) specificity, and surf...
Autores principales: | Deisting, Wibke, Raum, Tobias, Kufer, Peter, Baeuerle, Patrick A., Münz, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624873/ https://www.ncbi.nlm.nih.gov/pubmed/26510188 http://dx.doi.org/10.1371/journal.pone.0141669 |
Ejemplares similares
-
Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells
por: Herrmann, Ines, et al.
Publicado: (2010) -
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
por: Kebenko, Maxim, et al.
Publicado: (2018) -
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies
por: Münz, Markus, et al.
Publicado: (2010) -
The detection of EpCAM(+) and EpCAM(–) circulating tumor cells
por: Wit, Sanne de, et al.
Publicado: (2015) -
EpCAM (CD326) finding its role in cancer
por: Baeuerle, P A, et al.
Publicado: (2007)